Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trialcnbc
Lilly’s triple agonist, retreutide, demonstrated significant reductions in A1C and weight in the first phase 3 trial for the treatment of type 2 diabetes.Eli Lilly
Study finds record weight loss from Lilly’s experimental diabetes shotbloomberg.com
Lilly’s Triple-G Bet Lowers Blood Sugar, Helps 16.8% Weight Loss in Phase 3 Diabetes Trialfierce biotech
Lilly’s next-generation obesity drug shows reduction in blood sugar levels in trialsyahoo finance
